허혈뇌졸중 환자들의 발병 전 약물 순응과 임상적 의의: 일개병원기반 조사
Prestroke Medication Adherence and its Clinical Significance in Patients With Ischemic Stroke: Single Hospital-Based Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Medication adherence (MA) is poor among patients with chronic illnesses, such as those involving the risk factors of stroke. However, the impacts of poor MA on the modifiable risk factors of stroke are not well known. Methods: We evaluated the MA for the control of hypertension, diabetes, hyperlipidemia, and previous ischemic stroke among consecutive patients with ischemic stroke within 7 days of symptom onset. Nonadherence was defined as taking doctor‐prescribed medications for less than 3 weeks during the previous month. Demographic data, risk factor profile,stroke mechanism, and baseline score on the National Institutes of Health Stroke Scale (NIHSS) were compared among patients with nonadherence and those without. Results: Among 1133 patients with at least one medicated risk factor, the rates of nonadherence in hypertension,diabetes, hyperlipidemia, and previous ischemic stroke were 18.5%, 15.3%, 30.3%, and 28.1%, respectively. Overall,27.4% of patients with more than one risk factor presented nonadherence, with a predilection toward being male (male,63.9% vs. female, 56.1%, p=0.02) and younger (mean age 64.9 years vs. 66.4 years, p=0.01). Stroke severity according to MA did not differ using either crude analysis (NIHSS score: 5.5±5.9 vs. 5.4±5.5, p=0.71) or multivariable analysis after log transformation. The prevalence of nonadherence was low for large‐artery disease and small‐vessel occlusion, and high for cardioembolism. Conclusions: Prestroke poor MA for the major risk factors was common among patients with chronic illnesses, and was more frequent in younger male patients. Stroke severity was not affected by MA during the month preceding stroke.
Abstract
Background: Medication adherence (MA) is poor among patients with chronic illnesses, such as those involving the risk factors of stroke. However, the impacts of poor MA on the modifiable risk factors of stroke are not well known. Methods: We evaluated the MA for the control of hypertension, diabetes, hyperlipidemia, and previous ischemic stroke among consecutive patients with ischemic stroke within 7 days of symptom onset. Nonadherence was defined as taking doctor‐prescribed medications for less than 3 weeks during the previous month. Demographic data, risk factor profile,stroke mechanism, and baseline score on the National Institutes of Health Stroke Scale (NIHSS) were compared among patients with nonadherence and those without. Results: Among 1133 patients with at least one medicated risk factor, the rates of nonadherence in hypertension,diabetes, hyperlipidemia, and previous ischemic stroke were 18.5%, 15.3%, 30.3%, and 28.1%, respectively. Overall,27.4% of patients with more than one risk factor presented nonadherence, with a predilection toward being male (male,63.9% vs. female, 56.1%, p=0.02) and younger (mean age 64.9 years vs. 66.4 years, p=0.01). Stroke severity according to MA did not differ using either crude analysis (NIHSS score: 5.5±5.9 vs. 5.4±5.5, p=0.71) or multivariable analysis after log transformation. The prevalence of nonadherence was low for large‐artery disease and small‐vessel occlusion, and high for cardioembolism. Conclusions: Prestroke poor MA for the major risk factors was common among patients with chronic illnesses, and was more frequent in younger male patients. Stroke severity was not affected by MA during the month preceding stroke.
참고문헌 (29)
- Korean Stroke Society, "Textbook of stroke. 1st ed", ~ (2009)
- Goldstein LB, "Primary prevention of ischemic stroke: a guideline from the American Heart Association", American Stroke Association stroke council: cosponsored by the Atherosclerotic Peripheral Vascular Disease interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline, 2006, pp.37, 1583~1633
- Mehta RH, "Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry", Eur Heart J, 29, pp.3052~3060 (2008)
- Rasmussen JN, "Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction", JAMA, 297, pp.177~186 (2007)
- Gehi AK, "Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: The heart and soul study", Arch Intern Med, 167, pp.1798~1803 (2007)
- Osterberg L, "Adherence to medication", N Engl J Med, 353, pp.487~497 (2005)
- 유경호, "한국 뇌졸중 자료은행에 등록된 10,811명의 급성기 허혈성 뇌졸중 환자 분석: 병원기반 다의료기관 전향적 자료등록 연구", 대한신경과학회지, 24(6), pp.535~543 (2006), 대한신경과학회
- Deplanque D, "lipid-lowering drug use, and physical activity decrease ischemic stroke severity", Neurology, 67, pp.1403~1410 (2006)
- Selim M, "Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity", BMC Neurol, 5, pp.10~ (2005)
- Laowattana S, "Protective effects of beta-blockers in cerebrovascular disease", Neurology, 68, pp.509~514 (2007)
- Sanossian N, "Premorbid antiplatelet use and ischemic stroke outcomes", Neurology, 66, pp.319~323 (2006)
- Kunte H, "Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke", Stroke, 38, pp.2526~2530 (2007)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Ho PM, "Medication adherence: its importance in cardiovascular outcomes", Circulation, 119, pp.3028~3035 (2009)
- Amarenco P, "Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial", Stroke, 40, pp.2486~2492 (2009)
- Hylek EM, "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation", N Engl J Med, 349, pp.1019~1026 (2003)
- Selvin E, "Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus", Ann Intern Med, 141, pp.421~431 (2004)
- Haynes RB, "Helping patients follow prescribed treatment: clinical applications", JAMA, 288, pp.2880~2883 (2002)
- Jackevicius CA, "Adherence with statin therapy in elderly patients with and without acute coronary syndromes", JAMA, 288, pp.462~467 (2002)
- Kettani FZ, "Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention", Stroke, 40, pp.213~220 (2009)
- Mitka M, "Cardiologists like statins-more than patients do", JAMA, 286, pp.2799~2800 (2001)
- Blanco M, "Statin treatment withdrawal in ischemic stroke: a controlled randomized study", Neurology, 69, pp.904~910 (2007)
- Greisenegger S, "Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events", J Neurol Sci, 221, pp.5~10 (2004)
- Hyre AD, "Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting", J Clin Hypertens (Greenwich), 9, pp.179~186 (2007)
- Reeves MJ, "Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes", Lancet Neurol, 7, pp.915~926 (2008)
- Dick P, "Gender differences in outcome of conservatively treated patients with asymptomatic high grade carotid stenosis", Stroke, 36, pp.1178~1183 (2005)
- Jensen MK, "Obesity, behavioral lifestyle factors, and risk of acute coronary events", Circulation, 117, pp.3062~3069 (2008)
- Brookhart MA, "Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect", Am J Epidemiol, 166, pp.348~354 (2007)